​

Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRMY Stock Forecast

Harmony Biosciences (HRMY) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $48.17, with a high of $62.00 and a low of $31.00. This represents a 73.34% increase from the last price of $27.79.

$25 $33 $41 $49 $57 $65 High: $62 Avg: $48.17 Low: $31 Last Closed Price: $27.79

HRMY Stock Rating

Harmony Biosciences stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (76.92%), 1 Hold (7.69%), 2 Sell (15.38%), and 0 Strong Sell (0.00%).

Buy
Total 13 2 1 10 0 Strong Sell Sell Hold Buy Strong Buy

HRMY Price Target Upside V Benchmarks

TypeNameUpside
StockHarmony Biosciences73.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2411
Avg Price Target$40.50$43.00$45.00
Last Closing Price$27.79$27.79$27.79
Upside/Downside45.74%54.73%61.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26244-111
Feb, 26271-111
Jan, 26271-111
Dec, 25271-111
Nov, 25361-111
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 23, 2026Deutsche Bank$31.00$29.166.31%11.55%
Feb 19, 2026Mizuho Securities$50.00$35.2841.72%79.92%
Feb 11, 2026Youn ShimUBS$46.00$37.9321.28%65.53%
Jan 08, 2026Truist Financial$45.00$37.5519.84%61.93%
Dec 01, 2025Mizuho Securities$46.00$35.2930.35%65.53%
Nov 24, 2025Andreas ArgyridesOppenheimer$62.00$34.3180.71%123.10%
Oct 29, 2025Mizuho Securities$36.00$29.6421.46%29.54%
Oct 15, 2025UBS$43.00$26.8560.15%54.73%
Sep 25, 2025H.C. Wainwright$55.00$27.04103.40%97.91%
Jul 10, 2025Corinne JohnsonGoldman Sachs$33.00$34.33-3.87%18.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 23, 2026Deutsche BankBuyHolddowngrade
Feb 11, 2026UBSBuyNeutraldowngrade
Dec 03, 2025H.C. WainwrightBuyBuyhold
Nov 24, 2025OppenheimerOutperformOutperformhold
Jul 10, 2025Deutsche BankBuyBuyhold
Oct 30, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 30, 2024OppenheimerOutperformOutperformhold
Oct 30, 2024Goldman SachsSellSellhold
Oct 29, 2024UBSBuyBuyhold
Oct 02, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.60$3.07$2.17$2.56$2.76---
Avg Forecast$0.64$2.79$2.42$2.35$3.34$4.68$6.61$11.05
High Forecast$0.66$2.92$2.46$2.54$3.99$6.02$10.42$11.50
Low Forecast$0.62$2.63$2.38$2.07$2.01$3.15$4.68$10.66
Surprise %-6.25%10.04%-10.33%8.94%-17.37%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$305.44M$437.86M$582.02M$714.73M$868.45M---
Avg Forecast$303.77M$436.79M$582.76M$713.65M$852.00M$1.05B$1.31B$1.83B
High Forecast$311.41M$452.88M$583.40M$713.68M$876.86M$1.05B$1.35B$1.89B
Low Forecast$294.91M$418.27M$582.11M$713.61M$827.13M$1.05B$1.27B$1.78B
Surprise %0.55%0.24%-0.13%0.15%1.93%---

Net Income Forecast

$0 $140M $280M $420M $560M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.60M$181.47M$128.85M$145.49M$158.69M---
Avg Forecast$121.44M$58.46M$128.85M$139.23M$206.35M$281.05M$390.23M$667.32M
High Forecast$149.49M$74.29M$163.31M$153.53M$240.96M$363.44M$629.08M$694.25M
Low Forecast$93.40M$42.64M$94.40M$124.93M$121.42M$190.17M$282.54M$643.53M
Surprise %-71.51%210.39%-4.50%-23.10%---

HRMY Forecast FAQ

Is Harmony Biosciences stock a buy?

Harmony Biosciences stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Harmony Biosciences is a favorable investment for most analysts.

What is Harmony Biosciences's price target?

Harmony Biosciences's price target, set by 13 Wall Street analysts, averages $48.17 over the next 12 months. The price target range spans from $31 at the low end to $62 at the high end, suggesting a potential 73.34% change from the previous closing price of $27.79.

How does Harmony Biosciences stock forecast compare to its benchmarks?

Harmony Biosciences's stock forecast shows a 73.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Harmony Biosciences over the past three months?

  • March 2026: 18.18% Strong Buy, 36.36% Buy, 36.36% Hold, 0% Sell, 9.09% Strong Sell.
  • February 2026: 18.18% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.
  • January 2026: 18.18% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.

What is Harmony Biosciences’s EPS forecast?

Harmony Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $4.68, marking a 69.57% increase from the reported $2.76 in 2025. Estimates for the following years are $6.61 in 2027, and $11.05 in 2028.

What is Harmony Biosciences’s revenue forecast?

Harmony Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $1.05B, reflecting a 20.65% increase from the reported $868.45M in 2025. The forecast for 2027 is $1.31B, and $1.83B for 2028.

What is Harmony Biosciences’s net income forecast?

Harmony Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $281.05M, representing an 77.11% increase from the reported $158.69M in 2025. Projections indicate $390.22M in 2027, and $667.32M in 2028.